H. Hamano

发表

Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice

T. Meyer, M. Takei, K. Yoshinaga, 2010, Molecular pain.

Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.

M. Takei, K. Yoshinaga, N. Kobayashi, 2010, Biological & pharmaceutical bulletin.

Effect of polaprezinc on taste disorders in zinc‐deficient rats

M. Takei, K. Yoshinaga, Runa Eta, 2006, BioFactors.

Delayed induction of telomere instability in normal human fibroblast cells by ionizing radiation.

Keiji Suzuki, S. Kodama, Masatoshi Suzuki, 2004, Journal of radiation research.

Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain.

M. Takei, K. Yoshii, Y. Kawabata, 2010, Biological & pharmaceutical bulletin.

Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro

S. Watson, M. Takei, Takao Tanaka, 2008, Cancer Chemotherapy and Pharmacology.

Serum tau protein level serves as a predictive factor for neurological prognosis in neonatal asphyxia

S. Hasegawa, T. Ichiyama, Kazumasa Takahashi, 2014, Brain and Development.

Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models

T. Morris, S. Watson, A. Grabowska, 2008, Regulatory Peptides.

Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats.

M. Takei, Y. Kawabata, Takayuki Horii, 2009, Life sciences.